Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau

Brain

Volumn 139, Issue 7, 2016, Pages 1919-1938

  Liu, Shi Jie ^a   Zheng, Ping ^a   Wright, David K ^a,b   Dezsi, Gabi ^a   Braine, Emma ^a   Nguyen, Thanh ^a   Corcoran, Niall M ^a   Johnston, Leigh A ^a,b   Hovens, Christopher M ^a   Mayo, Jamie N ^a   Hudson, Matthew ^a   Shultz, Sandy R ^a   Jones, Nigel C ^a   O'Brien, Terence J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

animal model; epilepsy; MRI; PR55; traumatic brain injury

Indexed keywords

CREATINE; DIAZEPAM; KAINIC ACID; N ACETYLASPARTIC ACID; PHOSPHOPROTEIN PHOSPHATASE 2A; SELENATE; TAU PROTEIN; AMINO ACID RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; PHOSPHOPROTEIN PHOSPHATASE 2; PPP2R2A PROTEIN, RAT; SELENIC ACID;

ADULT; AMYGDALA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ARTICLE; BRAIN CORTEX; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORPUS CALLOSUM; DOWN REGULATION; DRUG IMPLANTATION; ELECTROENCEPHALOGRAPHY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; EPILEPTIC STATE; EPILEPTOGENESIS; FRACTIONAL ANISOTROPY; HIPPOCAMPUS; HYPERPHOSPHORYLATION; IMMUNOREACTIVITY; KINDLING; LATERAL BRAIN VENTRICLE; LONG EVANS RAT; LONG TERM CARE; MALE; METABOLIC RATIO; NEUROTOXICITY; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RAT MODEL; TRAUMATIC EPILEPSY; VIDEORECORDING; WESTERN BLOTTING; ANIMAL; BRAIN; CHEMICALLY INDUCED; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; EPILEPSY; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHOSPHORYLATION; TRAUMATIC BRAIN INJURY; WISTAR RAT;

ANIMALS; ANTICONVULSANTS; BRAIN; BRAIN INJURIES, TRAUMATIC; DISEASE MODELS, ANIMAL; ELECTROENCEPHALOGRAPHY; EPILEPSY; EXCITATORY AMINO ACID AGONISTS; KAINIC ACID; KINDLING, NEUROLOGIC; MAGNETIC RESONANCE IMAGING; MALE; PHOSPHORYLATION; PROTEIN PHOSPHATASE 2; RATS; RATS, WISTAR; SELENIC ACID; TAU PROTEINS;

EID: 84977593215     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aww116     Document Type: Article

References (55)

1. Abramoff MD, Magelhaes PJ, Ram SJ. Image processing with Image J. Biophoton Int 2004; 11: 36-42.
2. Amatniek JC, Hauser WA, DelCastillo-Castaneda C, Jacobs DM, Marder K, Bell K, et al. Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia 2006; 47: 867-72.
3. Arias C, Montiel T, Pen a F, Ferrera P, Tapia R. Okadaic acid induces epileptic seizures and hyperphosphorylation of the NR2B subunit of the NMDA receptor in rat hippocampus in vivo. Exp Neurol 2002; 177: 284-91.
4. Aroniadou-Anderjaska V, Fritsch B, Qashu F, Braga MF. Pathology and pathophysiology of the amygdala in epileptogenesis and epilepsy. Epilepsy Res 2008; 78: 102-16.
5. Ashford JW, Adamson M, Beale T, La D, Hernandez B, Noda A, et al. MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer dementia. J. Alzheimers Dis 2010; 26 (Suppl 3): 331-6.
6. Begum N, Ragolia L. cAMP counter-regulates insulin-mediated protein phosphatase-2A inactivation in rat skeletal muscle cells. J Biol Chem 1996; 271: 31166-71.
7. Bennecib M, Gong CX, Grundke-Iqbal I, Iqbal K. Role of protein phosphatase-2A and-1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain. FEBS Lett 2000; 485: 87-93.
8. Bolognin S, Blanchard J, Wang X, Basurto-Islas G, Tung YC, Kohlbrenner E, et al. An experimental rat model of sporadic Alzheimer's disease and rescue of cognitive impairment with a neurotrophic peptide. Acta Neuropathol 2011; 123: 133-51.
9. Brand A, Richter-Landsberg C, Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 1993; 15: 289-98.
10. Briellmann RS, Kalnins RM, Berkovic SF, Jackson GD. Hippocampal pathology in refractory temporal lobe epilepsy: T2-weighted signal change reflects dentate gliosis. Neurology 2002; 58: 265-71.
11. Casillas-Espinosa PM, Hicks A, Jeffreys A, Snutch TP, O'Brien TJ, Powell KL. Z944, a novel selective t-type calcium channel antagonist delays the progression of seizures in the amygdala kindling model. PLoS One 2015; 10: e0130012.
12. Corcoran NM, Martin D, Hutter-Paier B, Windisch M, Nguyen T, Nheu L, et al. Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer's disease model. J Clin Neurosci 2010a; 17: 1025-33.
13. Corcoran NM, Hovens CM, Michael M, Rosenthal MA, Costello AJ. Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer. Br J Cancer 2010b; 103: 462-8.
14. Desikan RS, McEvoy LK, Thompson WK, Holland D, Roddey JC, Blennow K, et al. Amyloid-b associated volume loss occurs only in the presence of phospho-tau. Ann Neurol 2011; 70: 657-61.
15. Dudek FE, Staley KJ. The time course of acquired epilepsy: implications for therapeutic intervention to suppress epileptogenesis. Neurosci Lett 2011; 497: 240-6.
16. Fisher RS, van Emde Boas W, Blume W, Elger C, Genton P, Lee P, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005; 46: 470-2.
17. FrankóE, Joly O, Joly O. Evaluating Alzheimer's disease progression using rate of regional hippocampal atrophy. PLoS One 2012; 8: e71354.
18. Galanopoulou AS, Buckmaster PS, Staley KJ, Moshe SL, Perucca E, Engel J, et al. Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia 2012; 53: 571-82.
19. Gunbey HP, Ercan K, F|nd|koǧlu AS, Bilir E, Karaoglanoglu M, Komurcu F, et al. Secondary corpus callosum abnormalities associated with antiepileptic drugs in temporal lobe epilepsy. A diffusion tensor imaging study. Neuroradiol J 2011; 24: 316-23.
20. Hanger DP, Betts JC, Loviny TL, Blackstock WP, Anderton BH. New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J Neurochem 1998; 71: 2465-76.
21. Higuchi N, Hiramatsu K, Mulkern RV. A novel method for fat suppression in RARE sequences. Magn Reson Med 1992; 27: 107-17.
22. Iqbal K, Liu F, Gong CX, Alonso ADC, Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 2009; 118: 53-69.
23. Ittner LM, Gotz J. Amyloid-b and tau - A toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 2010; 12: 65-72.
24. Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 2001; 353: 417-39.
25. Janssens V, Longin S, Goris J. PP2A holoenzyme assembly: in cauda venenum (the sting is in the tail). Trends Biochem Sci 2008; 33: 113-21.
26. Jones NC, Nguyen T, Corcoran NM, Velakoulis D, Chen T, Grundy R, et al. Targeting hyperphosphorylated tau with sodium selenate suppresses seizures in rodent models. Neurobiol Dis 2012; 45: 897-901.
27. Jupp B, Williams J, Binns D, Hicks RJ, Cardamone L, Jones N, et al. Hypometabolism precedes limbic atrophy and spontaneous recurrent seizures in a rat model of TLE. Epilepsia 2012; 53: 1233-44.
28. Jupp B, Williams JP, Tesiram YA, Vosmansky M, O'Brien TJ. Hippocampal T2 signal change during amygdala kindling epileptogenesis. Epilepsia 2005; 47: 41-6.
29. Kharatishvili I, Immonen R, Grohn O, Pitkanen A. Quantitative diffusion MRI of hippocampus as a surrogate marker for post-traumatic epileptogenesis. Brain 2007; 130: 3155-68.
30. Kharatishvili I, Nissinen JP, McIntosh TK, Pitkanen A. A model of posttraumatic epilepsy induced by lateral fluid-percussion brain injury in rats. Neuroscience 2006; 140: 685-97.
31. Loscher W, Brandt C. Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. Pharmacol Rev 2010; 62: 668-700.
32. Machnes ZM, Huang TCT, Chang PKY, Gill R, Reist N, Dezsi G, et al. DNA methylation mediates persistent epileptiform activity in vitro and in vivo. PLoS One 2013; 8: e76299.
33. Mendez MF, Catanzaro P, Doss RC, ARguello R, Frey WH. Seizures in Alzheimer's disease: clinicopathologic study. J Geriatr Psychiatry Neurol 1993; 7: 230-3.
34. Morales I, Jiménez JM, Mancilla M, Maccioni RB. Tau oligomers and fibrils induce activation of microglial cells. J. Alzheimers Dis 2012; 37: 849-56.
35. Morimoto K, Fahnestock M, Racine RJ. Kindling and status epilepticus models of epilepsy: rewiring the brain. Prog Neurobiol 2004; 73: 1-60.
36. Palop J, Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol 2009; 66: 435-40.
37. Pitkanen A, Lukasiuk K. Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol 2011; 10: 173-86.
38. Powell KL, Ng C, O'Brien TJ, Xu SH, Williams DA, Foote SJ, et al. Decreases in HCN mRNA expression in the hippocampus after kindling and status epilepticus in adult rats. Epilepsia 2008; 49: 1686-95.
39. Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed 2001; 14: 260-4.
40. Qian W, Shi J, Yin X, Iqbal K, Grundke-Iqbal I, Gong CX, et al. PP2A regulates tau phosphorylation directly and also indirectly via activating GSK-3beta. J Alzheimers Dis 2009; 19: 1221-9.
41. Ramírez-Munguía N, Vera G, Tapia R. Epilepsy, neurodegeneration, and extracellular glutamate in the hippocampus of awake and anesthetized rats treated with okadaic acid. Neurochem Res 2003; 28: 1517-24.
42. Sen A, Thom M, Martinian L, Harding B, Cross JH, Nikolic M, et al. Pathological tau tangles localize to focal cortical dysplasia in older patients. Epilepsia 2007; 48: 1447-54.
43. Shi Y. Serine/threonine phosphatases: mechanism through structure. Cell 2009; 139: 468-84.
44. Shultz SR, Cardamone L, Liu YR, Hogan RE, Maccotta L, Wright DK, et al. Can structural or functional changes following traumatic brain injury in the rat predict epileptic outcome? Epilepsia 2013; 54: 1240-50.
45. Shultz SR, Tan XL, Wright DK, Liu SJ, Semple BD, Johnston L, et al. Granulocyte-macrophage colony-stimulating factor is neuroprotective in experimental traumatic brain injury. J Neurotrauma 2014; 31: 976-83.
46. Shultz SR, Wright DK, Zheng P, Stuchbery R, Liu S-J, Sashindranath M, et al. Sodium selenate reduces hyperphosphorylated tau and improves outcomes after traumatic brain injury. Brain 2015; 138: 1297-313.
47. Simonato M, Brooks-Kayal AR, Engel J, Galanopoulou AS, Jensen FE, Moshe SL, et al. The challenge and promise of anti-epileptic therapy development in animal models. Lancet Neurol 2014; 13: 949-60.
48. Sontag J-M, Nunbhakdi-Craig V, Montgomery L, Arning E, Bottiglieri T, Sontag E. Folate deficiency induces in vitro and mouse brain regionspecific downregulation of leucine carboxyl methyltransferase-1 and protein phosphatase 2A B(alpha) subunit expression that correlate with enhanced tau phosphorylation. J Neurosci 2008; 28: 11477-87.
49. Stejskal EO, Tanner JE. Spin diffusion measurements: spin echoes in the presence of a time dependent field gradient. J Chem Phys 1965; 42: 288-92.
50. Thom M, Liu JYW, Thompson P, Phadke R, Narkiewicz M, Martinian L, et al. Neurofibrillary tangle pathology and Braak staging in chronic epilepsy in relation to traumatic brain injury and hippocampal sclerosis: a post-mortem study. Brain 2011; 134: 2969-81.
51. Tringham E, Powell KL, Cain SM, Kuplast K, Mezeyova J, Weerapura M, et al. T-type calcium channel blockers that attenuate thalamic burst firing and suppress absence seizures. Sci Transl Med 2012; 4: 121ra19.
52. van Eersel J, Ke YD, Liu X, Delerue F, Kril JJ, Gotz J, et al. Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. Proc Natl Acad Sci USA 2010; 107: 13888-93.
53. Vespa P, Tubi M, Claassen J, Blanco M, McArthur D, Velazquez AG, et al. Metabolic crisis occurs with seizures and periodic discharges after brain trauma. Ann Neurol 2016; 79: 579-90.
54. Xu Y, Chen Y, Zhang P, Jeffrey PD, Shi Y. Structure of a protein phosphatase 2A holoenzyme: insights into B55-mediated Tau dephosphorylation. Molecular Cell 2008; 31: 873-85.
55. Zilka N, Stozicka Z, Kovac A, Pilipcinec E, Bugos O, Novak M. Human misfolded truncated tau protein promotes activation of microglia and leukocyte infiltration in the transgenic rat model of tauopathy. J Neuroimmunol 2008; 209: 16-25.